Biospecifics Technologies Quick Ratio (BSTC) starting from the third quarter 2020 to third quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Biospecifics Technologies Corp  (NASDAQ: BSTC)

Biospecifics Technologies's Quick Ratio

BSTC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Biospecifics Technologies's Cash & cash equivalent, this led to improvement in Biospecifics Technologies's Quick Ratio to 56.27, above Biospecifics Technologies Corp average Quick Ratio.

Within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Quick Ratio than Biospecifics Technologies in third quarter 2020. While Quick Ratio total ranking has improved so far during the Q3 2020 to 71, from total ranking in the second quarter 2020 at 154.

Explain Quick Ratio?
How much Cash & cash equivalents BSTC´s has?
What are BSTC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BSTC Quick Ratio (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3
Y / Y Current Liabilities Change 75.69 % 141.7 % -10.7 % -45.94 % -51.55 %
Y / Y Cash & cash equivalent Change 5.94 % 16.15 % 23.34 % 10.33 % 13.99 %
Quick Ratio MRQ 56.27 25.78 31.14 65.94 93.32
BSTC's Total Ranking # 71 # 154 # 116 # 62 # 47
Seq. Current Liabilities Change -59.88 % 14.8 % 147.26 % 54.28 % -44.81 %
Seq. Cash & cash equivalent Change -12.45 % -4.96 % 16.79 % 9.02 % -4.01 %



Quick Ratio third quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 18
Overall Market # 71


Quick Ratio Statistics
High Average Low
93.32 26.95 3.77
(Sep 30 2019)   (Mar 31 2012)




Financial Statements
Biospecifics Technologies's Current Liabilities $ 2 Millions Visit BSTC's Balance sheet
Biospecifics Technologies's Cash & cash equivalent $ 87 Millions Visit BSTC's Balance sheet
Source of BSTC's Sales Visit BSTC's Sales by Geography


Cumulative Biospecifics Technologies's Quick Ratio

BSTC's Quick Ratio for the trailling 12 Months

BSTC Quick Ratio

 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth 15.66 % -2.41 % -31.45 % -32.55 % -19.69 %
Y / Y Cash & cash equivalent TTM Growth 14.05 % 16.1 % 18.72 % 21.5 % 5 %
Quick Ratio TTM 37.61 39.75 50.32 45.04 38.14
Total Ranking TTM # 2716 # 2658 # 28 # 2520 # 20
Seq. Current Liabilities TTM Growth 7.05 % 31.43 % -5.3 % -13.19 % -9.67 %
Seq. Cash & cash equivalent TTM Growth 1.3 % 3.82 % 5.79 % 2.51 % 3.12 %

Quick ratio ranking by company, industry and sector >> Back to BSTC Financial Strength Comparisons >> Go to Compare BSTC Quick Ratio to its Competitors

On the trailing twelve months basis Due to drop in Current Liabilities in the Q3 2020 to $1.54 millions, cumulative Quick Ratio decreased to 37.61 above the BSTC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 426 other companies have achieved higher Quick Ratio than Biospecifics Technologies. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from 2658 to 2716.

Explain Quick Ratio?
How much Cash & cash equivalents BSTC´s has?
What are BSTC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 427
Healthcare Sector # 769
Within the Market # 2716


trailing twelve months Quick Ratio Statistics
High Average Low
49.84 27.11 12
(Mar 31 2020)   (Dec. 30, 2013)




Companies with similar Quick Ratio in the quarter ending Sep 30 2020, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2020 MRQ Cash & cash equivalentSep 30 2020 MRQ Current Liabilities
Akouos inc   133.48 $ 320.074  Millions$ 2.398  Millions
Innoviva Inc   122.93 $ 479.193  Millions$ 3.898  Millions
Aptinyx Inc   105.28 $ 103.810  Millions$ 0.986  Millions
23andme Holding Co  93.89 $ 177.108  Millions$ 1.886  Millions
Dyne Therapeutics Inc   81.15 $ 379.606  Millions$ 4.678  Millions
Turning Point Therapeutics Inc.  68.67 $ 711.388  Millions$ 10.359  Millions
Pmv Pharmaceuticals Inc   68.14 $ 373.150  Millions$ 5.476  Millions
Karuna Therapeutics Inc   67.38 $ 344.897  Millions$ 5.119  Millions
Biovie Inc   64.94 $ 13.196  Millions$ 0.203  Millions
Annovis Bio Inc   63.23 $ 8.841  Millions$ 0.140  Millions
Aditxt Inc   62.27 $ 26.476  Millions$ 0.425  Millions
Biospecifics Technologies Corp  56.27 $ 86.718  Millions$ 1.541  Millions
Genprex Inc   56.05 $ 21.058  Millions$ 0.376  Millions
Revelation Biosciences Inc   54.27 $ 3.321  Millions$ 0.061  Millions
Enliven Therapeutics Inc   50.95 $ 96.089  Millions$ 1.886  Millions
Nextcure Inc   50.72 $ 291.206  Millions$ 5.741  Millions
Essa Pharma inc   49.51 $ 78.332  Millions$ 1.582  Millions
Seres Therapeutics Inc   48.04 $ 297.914  Millions$ 6.201  Millions
Galectin Therapeutics Inc   47.11 $ 32.556  Millions$ 0.691  Millions
Lantern Pharma Inc   45.07 $ 41.605  Millions$ 0.923  Millions
Psyence Biomedical ltd   44.85 $ 1.135  Millions$ 0.025  Millions
Arena Pharmaceuticals Inc   43.75 $ 1,167.864  Millions$ 26.697  Millions
Annexon Inc   41.24 $ 370.686  Millions$ 8.988  Millions
Xbiotech Inc   38.47 $ 238.431  Millions$ 6.198  Millions
Infinity Pharmaceuticals Inc   36.47 $ 41.285  Millions$ 1.132  Millions
Relmada Therapeutics Inc  36.33 $ 123.138  Millions$ 3.390  Millions
Alx Oncology Holdings Inc  36.05 $ 259.484  Millions$ 7.197  Millions
Nkarta Inc   34.50 $ 329.759  Millions$ 9.559  Millions
Repare Therapeutics Inc   34.13 $ 347.872  Millions$ 10.193  Millions
Trevena inc   33.47 $ 112.682  Millions$ 3.367  Millions

Date modified: 2026-09-26T07:12:56+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.